Company intelligence / Profile preview

Ocelot Bio

San Diego, California, United Statesocelotbio.com ↗

Ownership: Private
Employees: ~30
Development stage: Phase 2

Overview

Ocelot Bio’s lead candidate, OCE‑205, is a therapeutic peptide designed to selectively address portal hypertension-induced complications in end-stage liver disease. The company has initiated a Phase 2 clinical trial for HRS-AKI and received Orphan Drug Designation from the FDA for this indication. No active trials are currently listed on ClinicalTrials.gov as of the latest available data.

Therapeutic areas: GastroenterologyNephrology
Modalities: Peptides (therapeutic peptide)
Industry: Biotech

Drug pipeline

1 asset

OCE-205

Beyond the preview

Go deeper on Ocelot Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ocelot Bio.

Explore the full profile